A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Ivan De Dios(Georgia Southern University), Benjamin M. Parsons(Gundersen Health System), A Tzankov(NewYork–Presbyterian Hospital), Carlo Visco(University of Verona), Hua You(Soochow University), Youli Zu(Methodist Hospital), Maher Albitar(Center for Genomic Science), Wayne Tam(Cornell University), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Hongwei Zhang(Georgia Southern University), J. Han van Krieken(Radboud University Nijmegen), Miguel A. Piris(Northwestern University), Eric D. Hsi(Cleveland Clinic), April Chiu(Cornell University), Yong Li(Baylor College of Medicine), Bing Xu(First Affiliated Hospital of Xiamen University), Hongwei Zhang(Georgia Southern University), Feng Zhu(University Hospital of Basel), Maurilio Ponzoni(San Raffaele University of Rome), Jane N. Winter(Northwestern University), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center), Hong Zhang(Georgia Southern University), Hong Zhang(Baylor College of Medicine), Babak Shahbaba(University of California, Irvine), Jooryung Huh(Asan Medical Center), Michael Møller(Hospital South West Jutland)
Cited by 41
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523